Scientists test new pill to fight tough ovarian cancer
NCT ID NCT06084416
Summary
This study aims to find the best dose of a new oral drug called sovilnesib for people with advanced ovarian cancer that has stopped responding to standard platinum-based chemotherapy. About 120 participants will take different doses to see which one is safest and shows the most promise in shrinking tumors. The main goal is to identify the recommended dose for larger future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Corewell Health
Grand Rapids, Michigan, 49503, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Georgia Cancer Center Augusta University
Atlanta, Georgia, 30912, United States
-
Hoag Memorial Hospital
Newport Beach, California, 92663, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10128, United States
-
Johns Hopkins Hospital
Baltimore, Maryland, 21287, United States
-
MUSC Hollings Cancer Center
Charleston, South Carolina, 29020, United States
-
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma, 73117, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
-
The University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
-
UCLA
Los Angeles, California, 90095, United States
-
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205, United States
Conditions
Explore the condition pages connected to this study.